53 completed, 10 terminated, 7 active not recruiting, 7 unknown. 52 Phase 2, 32 Phase 1, 11 Phase 3, 2 Not applicable, 1 Phase 4.
Follow Pegylated Liposomal Doxorubicin Hydrochloride: new trials by email Literature Review of Pegylated Liposomal Doxorubicin Hydrochloride trials Research Report on Pegylated Liposomal Doxorubicin Hydrochloride
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy Anti-VEGF Monoclonal Antibody, Bevacizumab, Biospecimen Collection - Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Fallopian Tube High Grade Serous Adenocarcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 87 | 2026-09-24 | 2026-10-20 |
| Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer Biopsy, Biospecimen Collection, Computed Tomography - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 2 | Recruiting | Roswell Park Cancer Institute | 30 | 2026-03-03 | 2026-04-24 |
| Pyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer Pyrotinib Maleate, Trastuzumab (H, 8mg/kg, pegylated liposomal doxorubicin hydrochloride - HER2-positive Breast Cancer | Phase 2 | Recruiting | Hebei Medical University Fourth Hospital | 182 | 2024-04-30 | 2026-06-09 |
| Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Dedifferentiated Liposarcoma, Metastatic Leiomyosarcoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 30 | 2024-02-06 | 2026-10-22 |
| A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Bendamustine, Brentuximab Vedotin - Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma | Phase 3 | Withdrawn | National Cancer Institute (NCI) | 2023-08-10 | 2024-03-20 | |
| Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy Computed Tomography, Copanlisib Hydrochloride, Magnetic Resonance Imaging - Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2022-06-30 | 2023-09-26 | |
| Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents Biospecimen Collection, Cediranib Maleate, Computed Tomography - Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 120 | 2021-06-10 | 2026-10-22 |
| Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer Bevacizumab, Fluorouracil, Leucovorin - Advanced Malignant Neoplasm, Colorectal Carcinoma Metastatic in the Liver | Phase 1 | Terminated | M.D. Anderson Cancer Center | 38 | 2020-06-23 | 2026-07-27 |
| A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer Biospecimen Collection, Computed Tomography, Echocardiography Test - Endometrial High Grade Endometrioid Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 55 | 2020-05-07 | 2026-07-20 |
| Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial Biopsy Procedure, Biospecimen Collection, Capecitabine - Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 2 | Recruiting | National Cancer Institute (NCI) | 115 | 2019-07-16 | 2026-10-21 |
| Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia Bortezomib, Daratumumab, Dexamethasone - Plasma Cell Leukemia | Phase 1 | Withdrawn | City of Hope Medical Center | 2018-09-18 | 2026-10-22 | |
| Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Atezolizumab, Bevacizumab, Computed Tomography - Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 444 | 2017-06-23 | 2026-10-22 |
| Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer Cediranib, Cediranib Maleate, Computed Tomography - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 582 | 2016-05-03 | 2026-10-01 |
| Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Biospecimen Collection, Carboplatin, Cediranib Maleate - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 579 | 2016-03-28 | 2026-10-01 |
| Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative Bevacizumab, Everolimus, Laboratory Biomarker Analysis - Invasive Breast Carcinoma, Triple-Negative Breast Carcinoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 17 | 2016-01-12 | 2024-02-13 |
| Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Bevacizumab, Gemcitabine Hydrochloride, Paclitaxel - Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma | Phase 2 | Completed | Mayo Clinic | 13 | 2015-07-21 | 2024-12-05 |
| MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer Bevacizumab, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis - Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 2 | Terminated | Mayo Clinic | 17 | 2015-03-13 | 2025-12-11 |
| Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer pegylated liposomal doxorubicin hydrochloride, epirubicin hydrochloride, carboplatin - Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer | Phase 2 | Active not recruiting | Rutgers, The State University of New Jersey | 62 | 2015-02-25 | 2023-03-29 |
| Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer Carboplatin, Cisplatin, Gemcitabine Hydrochloride - FIGO Stage IVA Ovarian Cancer, FIGO Stage IVB Ovarian Cancer | Phase 1 | Active not recruiting | City of Hope Medical Center | 40 | 2014-05-19 | 2026-03-05 |
| Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer Letrozole, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride - Borderline Ovarian Serous Tumor, Micropapillary Serous Carcinoma | Phase 2 / Phase 3 | Completed | National Cancer Institute (NCI) | 260 | 2014-04-11 | 2026-08-04 |
Showing 20 of 85. Sign in to see all of them.
Ovarian Neoplasms (21) · Fallopian Tube Neoplasms (20) · Breast Neoplasms (16) · Lymphoma (11) · Carcinoma, Ovarian Epithelial (9) · Sarcoma (9) · Multiple Myeloma (7) · Endometrial Neoplasms (6) · Lymphoma, Large B-Cell, Diffuse (6) · Neoplasms, Plasma Cell (6) · AIDS-related Kaposi sarcoma (4) · Breast Neoplasms, Male (4) · Brenner Tumor (4) · Triple Negative Breast Neoplasms (4) · Histiocytoma, Malignant Fibrous (3)
National Cancer Institute (NCI) (19) · Gynecologic Oncology Group (9) · Roswell Park Cancer Institute (8) · M.D. Anderson Cancer Center (4) · Memorial Sloan Kettering Cancer Center (4) · European Organisation for Research and Treatment of Cancer - EORTC (3) · Case Comprehensive Cancer Center (2) · City of Hope Medical Center (2) · Mayo Clinic (2) · NYU Langone Health (2) · SWOG Cancer Research Network (2) · University of Washington (2) · AGO Study Group (1) · AIDS Malignancy Consortium (1) · ARCAGY/ GINECO GROUP (1)
United States (73) · Canada (4) · Puerto Rico (4) · Switzerland (4) · United Kingdom (4) · Germany (3) · Italy (3) · Austria (2) · France (2) · Israel (2) · Japan (2) · Norway (2) · South Korea (2) · Australia (1) · Belgium (1)
Peter G. Rose, MD (3) · Jung-min Lee (2) · Matthew D. Volm, MD (2) · Myron S. Czuczman, MD (2) · Paula M. Fracasso, MD, PhD (2) · A P Chen (1) · Ajai Chari, MD (1) · Alexandra M. Levine, MD (1) · Amrita Krishnan (1) · Andreas du Bois, MD, PhD (1) · Anne Hamilton, MD (1) · Antonio Wolff (1) · Beth A. Overmoyer, MD, FACP (1) · Bhavana Pothuri (1) · Bradley Monk (1)
PMID 37185961, PMID 12947059, PMID 15721421, PMID 15975638, PMID 16478630, PMID 16520033, PMID 16959305, PMID 17426059, PMID 17846226, PMID 17910981, PMID 17949799, PMID 18452103, PMID 19433391, PMID 19464730, PMID 20357034, PMID 21824051, PMID 23045580, PMID 23169503, PMID 23640206, PMID 23735702, PMID 23969788, PMID 24285015, PMID 24656636, PMID 24779680, PMID 30633128, PMID 35123694, PMID 35170751, PMID 35290101, PMID 35357903, PMID 37043123, PMID 37148580, PMID 37229879, PMID 37407274, PMID 39361946
U10CA180868 (9), U10CA027469 (4), N01CM62204 (2), P30CA013330 (2), P30CA043703 (2), U10CA021115 (2), U10CA031946 (2), U10CA032102 (2), 2004 (1), 2005 (1), P30CA006973 (1), P30CA008748 (1), P30CA014236 (1), P30CA016087 (1), P30CA016672 (1)